Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. Our findings indicate that inhibition of Janus kinase 2 (Jak2) in Bcr–Abl+ cells overcomes IM resistance al...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072513/ |